– Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction – – Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on...
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the...
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer,...
Enter your information and we will be in touch with you.
News Sign Up
Sign up to receive news notifications.
Connect With a Rep
Enter your information and we will be in touch with you.
Learn More Today
Fill out the form below for more information.
Webinar Signup
Sign up to receive webinar notifications.
We use cookies to ensure that we give you the best experience on our website. More information about our site Terms of Use and Privacy Policy provide additional details. Continue on to our site only if you agree with these policies.
